An ‘innocent bystander’ in the booming biotech investor world is writing a blank check for $100M. Who’s going to cash it?
Srini Akkaraju’s LinkedIn profile describes his work as a “biotech investor (aka innocent bystander)” with tongue-in-cheek modesty. But he’s been deeply steeped in the ways of venture investing since leaving a BD job at Genentech in 2001, following a career path that wound through New Leaf and Sofinnova Ventures in Menlo Park. And now he’s executing a quick flip on Wall Street for the latest in a series of biotech blank check companies to debut this year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.